ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.
BNT162b2
COVID
SARS-CoV
anaphylaxis
mRNA
severe allergic reactions
vaccines
virus
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
23
12
2020
accepted:
28
12
2020
pubmed:
31
12
2020
medline:
22
6
2021
entrez:
30
12
2020
Statut:
ppublish
Résumé
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1624-1628Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Raine J.Medicines and Healthcare products Regulatory Agency: Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine. 2020: GOV.UK. https://www.gov.uk/government/news/confirmation-of-guidance-to-vaccination-centres-on-managing-allergic-reactions-following-covid-19-vaccination-with-the-pfizer-biontech-vaccine. Accessed January 07, 2020.
England NHS. Patient Group Direction for COVID-19 mRNA vaccine BNT162b2. New York, NY: Pfizer/BioNTech; 2020. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/12/C0956-Patient-Group-Direction-for-COVID-19-mRNA-vaccine-BNT162b2-Pfizer-BioNTech-11-December-2020.pdf. Accessed December 15, 2020.
Weiland NL, Baker M, Thomas K. Alaska Health Workers Got Emergency Treatment After Receiving Pfizer's Vaccine in The New York Times. New York, NY: The New York Times; 2020. https://www.nytimes.com/2020/12/16/health/covid-pfizer-vaccine-allergic-reaction.html. Accessed January 07, 2020.
Caubet J-C, Ponvert C. Vaccine allergy. Immunol Allergy Clinics North America. 2014;34(3):597-613, ix.
Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Org J 2016;9(1):32.
McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol 2018;141(2):463-472.
Nilsson L, Brockow K, Alm J, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatric Allergy Immunol: Off Publ Eur Soc Pediatric Allergy Immunol. 2017;28(7):628-640.
Wood RA. Allergic reactions to vaccines. Pediatric Allergy Immunol: Off Publ Eur Soc Pediatric Allergy Immunol. 2013;24(6):521-526.
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020;13(10):100472.
WHO. ICD-11 for Mortality and Morbidity Statistics: 4A84 Anaphylaxis. Geneva, Switzerland: WHO; 2020. https://icd.WHO.int/browse11/l-m/en#/http%3a%2f%2fid.WHO.int%2ficd%2fentity%2f1868068711. Accessed December 17, 2020.
Yu JE, Lin RY. The Epidemiology of Anaphylaxis. Clin Rev Allergy Immunol 2018;54(3):366-374.
Turner PJ, Jerschow E, Umasunthar T, et al. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract 2017;5(5):1169-1178.
Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014;69(8):1026-1045.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. New Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577. Online ahead of print.
Pizzimenti S,Heffler E, Gentilcore E, et al. Macrogol hypersensitivity reactions during cleansing preparation for colon endoscopy. J Allergy Clin Immunol Pract. 2014;2(3):353-354.
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2016;46(7):907-922.
Wylon K, Dölle S, Worm M. Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin Immunol. 2016;12(1):67.
Zhou ZH, Stone CA, Jakubovic B, et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2020;31231-31239. https://doi.org/10.1016/j.jaip.2020.11.011
Cabanillas BA, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?. Allergy. 2021;76(6):1617-1618.
Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccines Immunother. 2015;11(9):2142-2157.
EMA/333964/2020. Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines. Amsterdam, The Netherlands: EMA; 2020. https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf. Accessed December 22, 2020.
EMA. Comirnaty - COVID-19 mRNA Vaccine (Nucleoside-modified). Amsterdam, The Netherlands: EMA; 2020. https://www.EMA.europa.eu/en/medicines/human/summaries-opinion/comirnaty. Accessed December 22, 2020.